Lv2
146 积分 2024-08-07 加入
Tu1470 HZ-W084, A NOVEL VAV1 DEGRADER, ALLEVIATES DISEASE PROGRESSION IN PRE-CLINICAL MURINE COLITIS MODEL
29天前
已完结
中国首次复发多发性骨髓瘤诊治指南（2026年版）
1个月前
已完结
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
3个月前
已完结
LB0008 SAP-001, A FIRST –IN-CLASS COMPOUND TARGETING A RENAL URATE TRANSPORTER, SHOWS POTENT SERUM URATE-LOWERING EFFECTS AND FAVORABLE SAFETY PROFILE IN A US PHASE 2b STUDY IN PATIENTS WITH REFRACTORY GOUT WITH OR WITHOUT PALPABLE TOPHI
6个月前
已完结
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
7个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
7个月前
已完结
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
8个月前
已完结
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
8个月前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
8个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
8个月前
已完结
皖公网安备34019202002308
